Home-Based Hematopoietic Cell Transplantation in the United States.

Journal Article (Journal Article)

Patients undergoing allogeneic (allo) and autologous (auto) hematopoietic cell transplantation (HCT) require extensive hospitalizations or daily clinic visits for the duration of their transplantation. Home HCT, wherein patients live at home and providers make daily trips to the patient's residence to perform assessments and deliver any necessary interventions, may enhance patient quality of life and improve outcomes. We conducted the first study of home HCT in the United States to evaluate this model in the US healthcare setting and to determine the effect on clinical outcomes and quality of life. This case-control study evaluated patients who received home HCT at Duke University in Durham, North Carolina, from November 2012 to March 2018. Each home HCT patient was matched with 2 controls from the same institution who had received standard treatment based on age, disease, and type of transplant for outcomes comparison. Clinical outcomes were abstracted from electronic health records, and quality of life was assessed via Functional Assessment of Cancer Therapy-Bone Marrow Transplant. Clinical outcomes were compared with Student's t-test or Fisher's exact test (continuous variables) or chi-square test (categorical variables). Quality of life scores were compared using the Student t-test. All analyses used a significance threshold of 0.05. Twenty-five patients received home HCT, including 8 allos and 17 autos. Clinical outcomes were not significantly different between the home HCT patients and their matched controls; home HCT patients had decreased incidence of relapse within 1 year of transplantation. Pre-HCT quality of life was well preserved for autologous home HCT patients. This Phase I study demonstrated that home HCT can be successfully implemented in the United States. There was no evidence that home HCT outcomes were inferior to standard-of-care treatment, and patients undergoing autologous home HCT were able to maintain their quality of life. A Phase II randomized trial of home versus standard HCT is currently underway to better compare outcomes and costs.

Full Text

Duke Authors

Cited Authors

  • Sung, AD; Giri, VK; Tang, H; Nichols, KR; Lew, MV; Bohannon, L; Ren, Y; Jung, S-H; Dalton, T; Bush, A; Van Opstal, J; Artica, A; Messina, J; Shelby, R; Frith, J; Lassiter, M; Burleson, J; Leonard, K; Potter, AS; Choi, T; Gasparetto, CJ; Horwitz, ME; Long, GD; Lopez, RD; Sarantopoulos, S; Chao, NJ

Published Date

  • April 2022

Published In

Volume / Issue

  • 28 / 4

Start / End Page

  • 207.e1 - 207.e8

PubMed ID

  • 35066211

Pubmed Central ID

  • PMC8977260

Electronic International Standard Serial Number (EISSN)

  • 2666-6367

Digital Object Identifier (DOI)

  • 10.1016/j.jtct.2022.01.015


  • eng

Conference Location

  • United States